

## **Top 1310 Generic and Biosimilar Pharmaceuticals (GLOBAL)**

Industry Analysis | 2025-02-03 | 1410 pages | Plimsoll

### **AVAILABLE LICENSES:**

- Electronic (PDF) €1100.00
- Hard Copy €1200.00

### **Report description:**

Plimsoll Publishings Generic and Biosimilar Pharmaceuticals (GLOBAL) Analysis provides a detailed overview of the Generic and Biosimilar Pharmaceuticals (GLOBAL) market and delivers a comprehensive individual analysis on the top 1310 companies, including BAYER AG, C.H. BOEHRINGER SOHN AG & CO. KG and TEVA API INDIA PRIVATE LIMITED.

This report includes a wealth of information on the financial trends over the past four years.

Plimsoll Publishings latest Generic and Biosimilar Pharmaceuticals (GLOBAL) analysis is ideal for anyone wanting to:

- See the market leaders
- Identify companies heading for failure
- Seek out the most attractive acquisition
- Analyse industry trends
- Benchmark their own financial performance

Using Plimsolls exclusive methodology, a quick glance of this Generic and Biosimilar Pharmaceuticals (GLOBAL) report will tell you that 183 companies have a declining Plimsoll financial rating, while 162 have shown good sales growth.

Each of the largest 1310 companies is meticulously scrutinised in an individual assessment and is analysed using the most up-to-date and current financial data.

Every business is examined on the following features:

- The Plimsoll Chart: A graphical assessment of a companys financial performance
- 
- 
- Four year assessment of the profit/loss and balance sheet
- A written summary highlighting key performance issues

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Subsequently, you will receive a thorough 100-page market analysis highlighting the latest changes in the Generic and Biosimilar Pharmaceuticals (GLOBAL) market.

This section includes:

- Best Trading Partners
- Sales Growth Analysis
- Profit Analysis
- Market Size
- Rankings

Established in 1987, Plimsoll provides busy managers with a set of tools to monitor the financial welfare of their company, their rivals, or those they wish to acquire. The reports are used to assess the attractiveness of potential acquisitions, gain better understanding of a market and identify sound companies with whom to trade.

### **Table of Contents:**

Plimsolls Generic and Biosimilar Pharmaceuticals (GLOBAL) analysis is the most definitive and accurate study of the Generic and Biosimilar Pharmaceuticals (GLOBAL) sector in 2017.

The report is split into three sections and uses both a written and graphical analysis - analysing the 1310 largest Generic and Biosimilar Pharmaceuticals (GLOBAL) companies.

The Generic and Biosimilar Pharmaceuticals (GLOBAL) report contains the most-up-to-date financial data and Plimsoll applies these figures to create their unique and authoritative analysis.

Indeed, the first section thoroughly scrutinises the market and this section includes the following:

- Best Trading Partners: These are companies that are winning in both sales and financial strength - for example ASTELLAS PHARMA INC. has been ranked as a best trading partner in the industry.
- Sales Growth Analysis: This section reviews the fastest growing and fastest shrinking company - for example HUONS GLOBAL CO., LTD. is among the fastest growing.
- Profit Analysis - Analysis of gross profit and pre-tax profit over the last ten years and a profitability summary comparing profits in the industry against small, medium and large companies.
- Market Size: Based on the largest 1310 companies, this is a comparison between last year's market size and the most current figure (This year the market has increased by 3.7%).
- Rankings: The top 50 companies ranked by: Market Share, Sales Growth, Gross Profit and Pre-tax Profit.

The next section focuses on company analysis and provides an in-depth analysis of the largest companies within the Generic and Biosimilar Pharmaceuticals (GLOBAL) industry.

Each business is analysed using Plimsolls unequivocal model and culminates in the production of the Plimsoll Chart. The Plimsoll Model uses a series of charts to graphically analyse an individual company and measure its ability to achieve sales growth while maintaining financial strength.

The Plimsoll Chart is a quick and dependable method of analysing a company's financial well-being. It's simple to understand: a

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

rising line is good news and a falling line is bad news.

Therefore, this company analysis will tell you if a company is:

- Strong or heading for failure
- Utilising their investments
- Becoming burdened by debt
- Getting the most from their resources

The Plimsoll Generic and Biosimilar Pharmaceuticals (GLOBAL) analysis also provides you with full business name and address, name and ages of directors and registration address.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Top 1310 Generic and Biosimilar Pharmaceuticals (GLOBAL)

Industry Analysis | 2025-02-03 | 1410 pages | Plimsoll

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

| Select license | License          | Price    |
|----------------|------------------|----------|
|                | Electronic (PDF) | €1100.00 |
|                | Hard Copy        | €1200.00 |
|                |                  | VAT      |
|                |                  | Total    |

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

|               |                      |                               |   |
|---------------|----------------------|-------------------------------|---|
| Email*        | <input type="text"/> | Phone*                        | <input type="text"/>                    |
| First Name*   | <input type="text"/> | Last Name*                    | <input type="text"/>                    |
| Job title*    | <input type="text"/> |                               |   |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/>                    |
| Address*      | <input type="text"/> | City*                         | <input type="text"/>                    |
| Zip Code*     | <input type="text"/> | Country*                      | <input type="text"/>                    |
|               |                      | Date                          | <input type="text" value="2025-06-06"/> |
|               |                      | Signature                     | <input type="text"/>                    |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com